You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
花旗:予阿里健康(0241.HK)買入評級 目標價50港元
格隆匯 11-25 12:36

花旗發表研究報吿指,阿里健康(0241.HK)2022財年上半年收入按年升31%至94億元人民幣,淨虧損2.32億元人民幣,去年同期淨利潤錄2.83億元人民幣,又指阿里健康收入增速放緩為預期之內,予目標價50港元及“買入”評級。

該行指,予公司“高風險”評級,可能妨礙股價達到目標價的下行風險包括,未能與阿里巴巴集團保持密切聯繫,互聯網醫療行業的政策阻力較大,新興業務板塊的不確定性及品牌風險等。

該行提及,公司表示淨虧損是由於對醫鹿APP、鄰里醫療、健康保險等業務的資源配置;技術和供應鏈產能的投資;及投資打造天貓醫藥平台和阿里健康大藥房的品牌知名度。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account